GHRH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
== Narcotics corruption == Drug-related corruption reportedly began to take a firm hold within Bolivia's military and security services under General Banzer's rule (1971–78). In 1980 the Junta of Commanders headed by Luis García Meza Tejada forced a violent coup d'etat—sometimes referred to as the Cocaine Coup - on 17 July. The García Meza regime (1980–81) was one of Bolivia's most flagrant examples of narcotics corruption. García Meza's so-called cocaine coup was itself generally believed to have been financed by the cocaine "mafia," which bribed certain military officers. García Meza reportedly ruled with an "inner cabinet" of leading civilians and military officers involved in the cocaine trade. Two of his ministers—Colonel Ariel Coca and Colonel Luis Arce Gómez—were well-known "godfathers" of the industry. By 1982 approximately 4,500 prosecutions were under way in connection with the embezzlement of state funds by civil servants, said to amount to a total of US$100 million. Garcia Meza's rule was so violent, and his regime so internationally isolated due to his drug trafficking, that he was forced to resign in 1981. His main collaborator, Colonel Luis Arce Gómez, was extradited to the United States, where he served a jail sentence for drug trafficking. In early 1986, Congress charged García Meza and fifty-five of his former colleagues with sedition, armed uprising, treason, genocide, murder, torture, fraud against the state, drug trafficking, crimes against the Constitution, and other crimes.
=== Sources for human stem cells === Most stem cells intended for regenerative therapy are generally isolated either from the patient's bone marrow or from adipose tissue. Mesenchymal stem cells can differentiate into the cells that make up bone, cartilage, tendons, and ligaments, as well as muscle, neural and other progenitor tissues. They have been the main type of stem cells studied in the treatment of diseases affecting these tissues. The number of stem cells transplanted into damaged tissue may alter the efficacy of treatment. Accordingly, stem cells derived from bone marrow aspirates, for instance, are cultured in specialized laboratories for expansion to millions of cells. Although adipose-derived tissue also requires processing prior to use, the culturing methodology for adipose-derived stem cells is not as extensive as that for bone marrow-derived cells. While it is thought that bone-marrow-derived stem cells are preferred for bone, cartilage, ligament, and tendon repair, others believe that the less challenging collection techniques and the multi-cellular microenvironment already present in adipose-derived stem cell fractions make the latter the preferred source for autologous transplantation. New sources of mesenchymal stem cells are being researched, including stem cells present in the skin and dermis which are of interest because of the ease at which they can be harvested with minimal risk to the animal.
=== Gut microbiota unaccustomed to endemic organisms === Foodborne illness often occurs as travelers' diarrhea in persons whose gut microbiota is unaccustomed to organisms endemic to the visited region. This effect of microbiologic naïveté is compounded by any food safety lapses in the food's preparation. Locals develop immunity to local food pathogens through repeated exposure, explaining why they often don't get sick from food that affects travelers. This immune adaptation involves developing specific defenses against common local bacteria, viruses, and parasites. Through this process, locals' immune systems produce a measured response that eliminates pathogens without triggering excessive inflammatory reactions, while travelers' immune systems often mount exaggerated responses to novel pathogens.
== Biology == A tropical species, the lesser mealworm thrives in warm, humid environments, both natural and established by humans. It inhabits caves, rodent nests, and the nests of birds, including kites, pigeons, hamerkop, house sparrow, and purple martin. It easily colonizes agricultural establishments with abundant food sources and warm conditions, such as grain processing and storage facilities and poultry housing. The beetle consumes a wide variety of materials, including litter, bird droppings and bat guano, mold, feathers, eggs, and carrion. It feeds on the eggs and larvae of other insects, such as the rice moth (Corcyra cephalonica). It also engages in cannibalism. It commonly feeds on sick or weakened live animals. When it lives in bird housing it may infest and consume dying birds, especially chicks. It was also once observed inhabiting the scrotum of a rat. The adult female beetle lays usually about 200 to 400 eggs, but it has been known to produce up to 2000. It lays eggs every few days throughout its life, which is generally up to one year long, or up to two years when it is reared in captivity. It deposits the eggs in litter, droppings, grain stores, or cracks in structures. The larvae emerge within a week and take 40 to 100 days to reach maturity, depending on conditions and the food supply. The larvae grow well in high humidity. They pupate alone in secure spots. They are quite active and mobile and burrow quickly when threatened. Larvae and adults are mainly nocturnal, becoming most active at dusk.
== Diagnosis == Diabetes of any type is typically diagnosed by a blood test showing unusually high blood sugar. The World Health Organization defines diabetes as blood sugar levels at or above 7.0 mmol/L (126 mg/dL) after fasting for at least eight hours, or a glucose level at or above 11.1 mmol/L (200 mg/dL) two hours after an oral glucose tolerance test. The American Diabetes Association additionally recommends a diagnosis of diabetes for anyone with symptoms of hyperglycemia and blood sugar at any time at or above 11.1 mmol/L, or glycated hemoglobin (hemoglobin A1C) levels at or above 48 mmol/mol (6.5%). Once a diagnosis of diabetes is established, type 1 diabetes is distinguished from other types by a blood test for the presence of autoantibodies that target various components of the beta cell. The most commonly available tests detect antibodies against glutamic acid decarboxylase, the beta cell cytoplasm, or insulin, each of which is targeted by antibodies in around 80% of type 1 diabetics. Some healthcare providers also have access to tests for antibodies targeting the beta cell proteins IA-2 and ZnT8; these antibodies are present in around 58% and 80% of people with type 1 diabetes, respectively. Some also test for C-peptide, a byproduct of insulin synthesis. Very low C-peptide levels are suggestive of type 1 diabetes. The median age of type 1 diabetes diagnosis in the United States is 24 years of age.
Sources: en.wikipedia.org
In an exclusive interview filmed at Howe's studio within the historic tower, the lead concept artist behind Peter Jackson's The Lord of the Rings and The Hobbit film trilogies endorsed augmented reality and the Cybel'Art protocol as the future of fantasy art, declaring: "Fantasy is a profession of the future through augmented reality and initiatives like yours."
Expression of foreign proteins requires the use of specialized expression vectors and often necessitates significant restructuring by foreign coding sequences. Recombinant DNA differs from genetic recombination in that the former results from artificial methods while the latter is a normal biological process that results in the remixing of existing DNA sequences in essentially all organisms.
== Awards == Horecker was elected to the National Academy of Sciences in 1961, and received many other awards, including the presidency of the American Society for Biochemistry and Molecular Biology (at the time the American Society of Biological Chemists), and was the first recipient of its Merck Award in 1981. In 1952 he received the Paul Lewis Award in Enzyme Chemistry (now the Pfizer Award in Enzyme Chemistry) from the Division of Biological Chemistry of the American Chemical Society. Horecker was twice nominated for the Nobel Prize in Chemistry, by Leopold Ružička in 1957, and by Felix Haurowitz in 1961.
Dispensing medications in a community pharmacy before the 1970s was a time-consuming operation. The pharmacist dispensed prescriptions in tablet or capsule form with a simple tray and spatula. Many new medications were developed by pharmaceutical manufacturers at an ever-increasing pace, and medications prices were rising steeply. A typical community pharmacist was working longer hours and often forced to hire staff to handle increased workloads which resulted in less time to focus on safety issues. These additional factors led to use of a machine to count medications. The original electronic portable digital tablet counting technology was invented in Manchester, England between 1967 and 1970 by the brothers John and Frank Kirby.
Sources: en.wikipedia.org
Pharmacometricians typically come from disciplines such as Pharmacy, Clinical pharmacology, Statistics, Medicine, or Engineering. The first professor of pharmacometrics was Mats Karlsson, Uppsala University.
The following figures were averaged from 2005 to 2007 adult data compiled by the CDC BRFSS program and 2003–2004 child data[A] from the National Survey of Children's Health. There is also data from a more recent 2016 CDC study of the 50 states plus the District of Columbia, Puerto Rico, the U.S. Virgin Islands and Guam. Care should be taken in interpreting these numbers, because they are based on self-report surveys which asked individuals (or, in case of children and adolescents, their parents) to report their height and weight. Height is commonly overreported and weight underreported, sometimes resulting in significantly lower estimates. One study estimated the difference between actual and self-reported obesity as 7% among males and 13% among females as of 2002, with the tendency to increase. The long-running REGARDS study, published in the journal of Obesity in 2014, brought in individuals from the nine census regions and measured their height and weight. The data collected disagreed with the data in the CDC's phone survey used to create the following chart. REGARDS found that the West North Central region (North Dakota, South Dakota, Minnesota, Missouri, Nebraska, and Iowa), and East North Central region (Illinois, Ohio, Wisconsin, Michigan, and Indiana) were the worst in obesity numbers, not the East South Central region (Tennessee, Mississippi, Alabama, Kentucky) as had been previously thought. Dr.
The development of the APCI interface for LC–MS started with Horning and collaborators in the early 1973. However, its commercial application was introduced at the beginning of the 1990s after Henion and collaborators improved the LC–APCI–MS interface in 1986. The APCI ion source/ interface can be used to analyze small, neutral, relatively non-polar, and thermally stable molecules (such as steroids, lipids, and fat soluble vitamins). These compounds are not well ionized using ESI. In addition, APCI can also handle mobile phase streams containing buffering agents. The liquid from the LC system is pumped through a capillary and there is also nebulization at the tip, where a corona discharge takes place. First, the ionizing gas surrounding the interface and the mobile phase solvent are subject to chemical ionization at the ion source. Later, these ions react with the analyte and transfer their charge. The sample ions then pass through small orifice skimmers by means of ion-focusing lenses. Once inside the high vacuum region, the ions are subject to mass analysis. This interface can be operated in positive and negative charge modes and singly-charged ions are mainly produced. APCI ion source can also handle flow rates between 500 and 2000 μl/min and it can be directly connected to conventional 4.6 mm ID columns.
In 1896, Viennese dermatologist Leopold Freund (1868-1943) used X-rays to treat patients for the first time. He successfully irradiated the hairy nevus of a young girl. In 1897, Hermann Gocht (1869–1931) published the treatment of trigeminal neuralgia with X-rays, and Alexei Petrovich Sokolov (1854-1928) wrote about radiotherapy for arthritis in the oldest radiology journal, Advances in the field of X-rays (RöFo). In 1922, X-rays were recommended as safe for many diseases and for diagnostic purposes. Radiation protection was limited to recommending doses that would not cause erythema (reddening of the skin). For example, X-rays were promoted as an alternative to tonsillectomy. It was also boasted that in 80% of cases of diphtheria carriers, Corynebacterium diphtheriae was no longer detectable within two to four days. In the 1930s, Günther von Pannewitz (1900–1966), a radiologist from Freiburg, Germany, perfected what he called X-ray stimulation radiation for degenerative diseases. Low-dose radiation reduces the inflammatory response of tissues. Until about 1960, children with diseases such as ankylosing spondylitis or favus (head fungus) were irradiated, which was effective but led to increased cancer rates among patients decades later. In 1926, the American pathologist James Ewing (1866-1943) was the first to observe bone changes as a result of radiotherapy, which he described as radiation osteitis (now Osteoradionecrosis). In 1983, Robert E. Marx stated that osteoradionecrosis is radiation-induced aseptic bone necrosis.
While research accelerators had once generated 70 percent of sales, industrial products now accounted for 80 percent. Despite the strategic pivot, HVEC struggled to achieve sustained profitability. Its subsidiaries faced intense competition from larger conglomerates. In 1981, HVEC divested from its accelerator manufacturing business. Two years later, it sold its Burlington manufacturing plant. The company refocused on smaller industrial products including specialty plastics, wire, industrial instruments, and electrical connectors. Through the 1980s, HVEC progressively sold these product lines to other manufacturing conglomerates. In 1988, private equity firm Hyde Park Partners bid to take HVEC private at roughly twice its prevailing share price. Though Levesque resisted, shareholders accepted the offer in 1989. Hyde Park dismissed existing management, sold remaining real estate, and relocated the headquarters to Charlestown, Massachusetts. The company filed for bankruptcy in 2005. Since 2019, corporate remnants have been held by Oak Point Partners.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.